# A Double-blind, Randomized, Single Centre, Vehicle-controlled Study to Evaluate the Safety and Tolerability of a New Topical Formulation Containing 0,09% Imiquimod (Limtop) in Healthy Subjects

> **NCT01567683** · PHASE1 · COMPLETED · sponsor: **Moberg Pharma AB**

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Imiquimod (topical use)

## Key facts

- **NCT ID:** NCT01567683
- **Lead sponsor:** Moberg Pharma AB
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2012-05-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01567683

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01567683, "A Double-blind, Randomized, Single Centre, Vehicle-controlled Study to Evaluate the Safety and Tolerability of a New Topical Formulation Containing 0,09% Imiquimod (Limtop) in Healthy Subjects". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01567683. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*